{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:41:11Z","timestamp":1794937271211,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7224\/A23275; CRUKD\/14\/007; UK C347\/A18077; C309\/A25144; CTRQQR-2021\\100009"],"award-info":[{"award-number":["C7224\/A23275; CRUKD\/14\/007; UK C347\/A18077; C309\/A25144; CTRQQR-2021\\100009"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","award":["NIHR202438"],"award-info":[{"award-number":["NIHR202438"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CRIS Cancer Foundation Experimental Cancer Medicine Centre Paul and Kathy Beaumont"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-62249-0","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T13:10:19Z","timestamp":1754053819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-5227","authenticated-orcid":false,"given":"Magnus T.","family":"Dillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-5733","authenticated-orcid":false,"given":"Emmanuel C.","family":"Patin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeane","family":"Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-3016","authenticated-orcid":false,"given":"Simon A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-257X","authenticated-orcid":false,"given":"Emma","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-3179","authenticated-orcid":false,"given":"Pablo","family":"Nenclares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Ryugenji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davina","family":"Northcote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Grove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3226-0515","authenticated-orcid":false,"given":"Christopher J.","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pettit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Tall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6572-1293","authenticated-orcid":false,"given":"Karen E.","family":"Swales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1503-3123","authenticated-orcid":false,"given":"Udai","family":"Banerji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2042-3380","authenticated-orcid":false,"given":"Alan A.","family":"Melcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin D.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,1]]},"reference":[{"key":"62249_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1535-7163.MCT-16-0239","volume":"16","author":"MT Dillon","year":"2017","unstructured":"Dillon, M. T. et al. Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei. Mol. Cancer Ther. 16, 25\u201334 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"62249_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat. Rev. Mol. Cell Biol. 9, 616\u2013627 (2008).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"62249_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clon.2014.01.009","volume":"26","author":"MT Dillon","year":"2014","unstructured":"Dillon, M. T., Good, J. S. & Harrington, K. J. Selective targeting of the G2\/M cell cycle checkpoint to improve the therapeutic index of radiotherapy. Clin. Oncol. (R. Coll. Radio.) 26, 257\u2013265 (2014).","journal-title":"Clin. Oncol. (R. Coll. Radio.)"},{"key":"62249_CR4","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","volume":"25","author":"MT Dillon","year":"2019","unstructured":"Dillon, M. T. et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin. Cancer Res. 25, 3392\u20133403 (2019).","journal-title":"Clin. Cancer Res."},{"key":"62249_CR5","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti, F. P. et al. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J. Clin. Investig. 128, 3926\u20133940 (2018).","journal-title":"J. Clin. Investig."},{"key":"62249_CR6","doi-asserted-by":"publisher","first-page":"e004306","DOI":"10.1136\/jitc-2021-004306","volume":"10","author":"EC Patin","year":"2022","unstructured":"Patin, E. C. et al. Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J. Immunother. Cancer 10, e004306 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"62249_CR7","doi-asserted-by":"publisher","first-page":"e175369","DOI":"10.1172\/JCI175369","volume":"134","author":"MT Dillon","year":"2024","unstructured":"Dillon, M. T. et al. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation. J. Clin. Invest. 134, e175369 (2024).","journal-title":"J. Clin. Invest."},{"key":"62249_CR8","first-page":"16","volume":"12","author":"MT Dillon","year":"2018","unstructured":"Dillon, M. T. et al. PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clin. Transl. Radiat. Oncol. 12, 16\u201320 (2018).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"62249_CR9","doi-asserted-by":"crossref","unstructured":"Lent soma scales for all anatomic sites. Int. J. Radiat. Oncol. Biol. Phys. 31, 1049\u20131091 (1995).","DOI":"10.1016\/0360-3016(95)90159-0"},{"key":"62249_CR10","doi-asserted-by":"crossref","unstructured":"Jones, G. N. et al. pRAD50: a novel and clinically applicable pharmacodynamic biomarker of both ATM and ATR inhibition identified using mass spectrometry and immunohistochemistry. Br. J. Cancer 119, 1233\u20131243 (2018).","DOI":"10.1038\/s41416-018-0286-4"},{"key":"62249_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. First-in-human trial of the oral ataxia telangiectasia and RAD3-Related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discov. 11, 80\u201391 (2021).","journal-title":"Cancer Discov."},{"key":"62249_CR12","doi-asserted-by":"crossref","unstructured":"Dillon, M. T. & Harrington, K. J. Targeting ATR for cancer therapy: ATR-targeted drug candidates. In Targeting the DNA Damage Response for Anti-Cancer Therapy (eds. Pollard J. & Curtin N. J.) 99\u2013127 (London: Springer; 2018).","DOI":"10.1007\/978-3-319-75836-7_5"},{"key":"62249_CR13","doi-asserted-by":"publisher","first-page":"5643","DOI":"10.1158\/1078-0432.CCR-24-0154","volume":"30","author":"V Ng","year":"2024","unstructured":"Ng, V. et al. Genotype-directed synthetic cytotoxicity of ATR inhibition with radiotherapy. Clin. Cancer Res. 30, 5643\u20135656 (2024).","journal-title":"Clin. Cancer Res."},{"key":"62249_CR14","doi-asserted-by":"crossref","unstructured":"McLaughlin, M. et al. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat. Rev. Cancer 20, 203\u2013217 (2020).","DOI":"10.1038\/s41568-020-0246-1"},{"key":"62249_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/path.5232","volume":"247","author":"AC Wilkins","year":"2019","unstructured":"Wilkins, A. C., Patin, E. C., Harrington, K. J. & Melcher, A. A. The immunological consequences of radiation-induced DNA damage. J. Pathol. 247, 606\u2013614 (2019).","journal-title":"J. Pathol."},{"key":"62249_CR16","doi-asserted-by":"publisher","first-page":"e000340","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"H Sheng","year":"2020","unstructured":"Sheng, H. et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J. Immunother. Cancer 8, e000340 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"62249_CR17","doi-asserted-by":"crossref","unstructured":"Patin, E. C. et al. Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy. Nat. Commun. 15, 6923 (2024).","DOI":"10.1038\/s41467-024-51236-6"},{"key":"62249_CR18","doi-asserted-by":"crossref","unstructured":"Yoneyama, M. et al. Longitudinal assessment of tumor-infiltrating lymphocytes in primary breast cancer following neoadjuvant radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 120, 862\u2013874 (2024).","DOI":"10.1016\/j.ijrobp.2024.04.065"},{"key":"62249_CR19","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.ijrobp.2018.01.005","volume":"100","author":"JG Steverink","year":"2018","unstructured":"Steverink, J. G. et al. Early tissue effects of stereotactic body radiation therapy for spinal metastases. Int. J. Radiat. Oncol. Biol. Phys. 100, 1254\u20131258 (2018).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"62249_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08507-3","volume":"12","author":"R Kotecha","year":"2022","unstructured":"Kotecha, R. et al. Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. Sci. Rep. 12, 4567 (2022).","journal-title":"Sci. Rep."},{"key":"62249_CR21","doi-asserted-by":"publisher","first-page":"CT198","DOI":"10.1158\/1538-7445.AM2023-CT198","volume":"83","author":"GN Jones","year":"2023","unstructured":"Jones, G. N. et al. Abstract CT198: immunomodulatory effects of the ATR inhibitor ceralasertib in a window of opportunity biomarker trial in patients with head and neck squamous cell carcinoma. Cancer Res. 83, CT198\u2013CT198 (2023).","journal-title":"Cancer Res."},{"key":"62249_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45996-4","volume":"15","author":"EL Hardaker","year":"2024","unstructured":"Hardaker, E. L. et al. The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment. Nat. Commun. 15, 1700 (2024).","journal-title":"Nat. Commun."},{"key":"62249_CR23","doi-asserted-by":"publisher","first-page":"e165615","DOI":"10.1172\/jci.insight.165615","volume":"8","author":"FP Vendetti","year":"2023","unstructured":"& Vendetti, F. P. et al. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy. JCI Insight 8, e165615 (2023).","journal-title":"JCI Insight"},{"key":"62249_CR24","first-page":"61","volume":"25","author":"GM Walls","year":"2020","unstructured":"Walls, G. M. et al. CONCORDE: a phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer. Clin. Transl. Radiat. Oncol. 25, 61\u201366 (2020).","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"62249_CR25","doi-asserted-by":"crossref","unstructured":"Javed, S. R. et al. CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. Br. J. Cancer 130, 467\u2013475 (2024).","DOI":"10.1038\/s41416-023-02542-1"},{"key":"62249_CR26","doi-asserted-by":"publisher","first-page":"S761","DOI":"10.1016\/j.annonc.2022.07.612","volume":"33","author":"S El Badri","year":"2022","unstructured":"El Badri, S. et al. 484P CHARIOT trial (cohort A2): a phase I dose-escalation study combining the ATR inhibitor berzosertib with cisplatin and capecitabine. Ann. Oncol. 33, S761 (2022).","journal-title":"Ann. Oncol."},{"key":"62249_CR27","doi-asserted-by":"publisher","first-page":"S842","DOI":"10.1016\/j.annonc.2022.07.780","volume":"33","author":"A Bhatia","year":"2022","unstructured":"Bhatia, A. et al. 656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma. Ann. Oncol. 33, S842 (2022).","journal-title":"Ann. Oncol."},{"key":"62249_CR28","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.1158\/1078-0432.CCR-21-1032","volume":"27","author":"TA Yap","year":"2021","unstructured":"Yap, T. A. et al. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study. Clin. Cancer Res. 27, 5213\u20135224 (2021).","journal-title":"Clin. Cancer Res."},{"key":"62249_CR29","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/ijgc-2021-002973","volume":"31","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S. et al. ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT\/GYN1\/NCRI). Int. J. Gynecol. Cancer 31, 1471\u20131475 (2021).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"62249_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","volume":"33","author":"R Kim","year":"2022","unstructured":"Kim, R. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann. Oncol. 33, 193\u2013203 (2022).","journal-title":"Ann. Oncol."},{"key":"62249_CR31","doi-asserted-by":"publisher","first-page":"e005041","DOI":"10.1136\/jitc-2022-005041","volume":"10","author":"M Kwon","year":"2022","unstructured":"Kwon, M. et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J. Immunother. Cancer 10, e005041 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"62249_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cjp2.103","volume":"4","author":"S Khalique","year":"2018","unstructured":"Khalique, S. et al. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. J. Pathol. Clin. Res. 4, 154\u2013166 (2018).","journal-title":"J. Pathol. Clin. Res."},{"key":"62249_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"62249_CR34","doi-asserted-by":"crossref","unstructured":"Schmidt, U., Weigert, M., Broaddus, C. & Myers, G. Cell detection with star-convex polygons. In Medical Image Computing and Computer Assisted Intervention \u2013 MICCAI 2018 (eds. Frangi, A. F. et al.) 265\u2013273 (Cham: Springer International Publishing, 2018).","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"62249_CR35","unstructured":"Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CMV) (Rockville, MD: Food and Drug Administration, 2018)."},{"key":"62249_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"62249_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"62249_CR38","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013).","journal-title":"Immunity"},{"key":"62249_CR39","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"62249_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-00783-w","volume":"12","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Med. 12, 86 (2020).","journal-title":"Genome Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62249-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T11:24:29Z","timestamp":1757330669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-62249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["62249"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-62249-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.E.S is an employee of The Institute of Cancer Research, which is involved in the development of PI3K, HSP90, HDAC, AKT, ROCK, RAF, CHK1, and HSF1 inhibitors. C.J.L. makes the following disclosures: receives and\/or has received research funding from: AstraZeneca, Merck KGaA, Artios, Neophore. Received consultancy, SAB membership or honoraria payments from: Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures. Has stock in: Tango, Ovibio, Hysplex, Tesselate. U.B. reports research funding, honoraria and advisory board membership for Chugai Pharmaceutical, Verastem Inc., and Carrick Therapeutics K.J.H. reports honoraria (inst.): ALX Pharma, Arch Oncology, AstraZeneca, Bicara Therapeutics, BMS, Boehringer Ingelheim, Codiak Biosciences, F-Star Therapeutics, Inzen Therapeutics, Merck Serono, Merus, MSD, Oncolys Biopharma, Pfizer, Replimune, VacV Biotherapeutics; Consulting or Advisory Role (inst.): Arch Oncology, AstraZeneca, BMS, Boehringer Ingelheim, Inzen Therapeutics, Merck Serono, MSD, Oncolys BioPharma, Replimune; Speakers\u2019 Bureau (inst.): BMS, Merck Serono, MSD; Research Funding (inst.): AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Replimune. E.D., S.A.S., N.S. are employees of AstraZeneca with stock ownership. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7064"}}